Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Patients with COPD and elevated eosinophils have an increased risk of exacerbations and COPD-related hospitalizations within a year. Sanofi and Regeneron are motivated to transform the treatment ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable ...

Sanofi—which co-markets the anti-inflammatory blockbuster Dupixent with Regeneron—has been undergoing a major pipeline shake-up in an effort to become “an immunoscience powerhouse ...

For Sanofi, the acquisition of DR-0201 represents the continuation of a push into the immunology space. Historically known for its plethora of vaccines, the company has seen financial success from ...

3 Year-21.26%-11.85% 29.25% 32.04% ...

which is marketed in collaboration with Regeneron REGN. This drug is currently a key top-line driver for both SNY and REGN. In 2024, Sanofi recorded more than €13 billion from Dupixent product ...

With the DR-0201 buy, Sanofi moves closer to its ambition of becoming an “the leading immunology company,” as Ashrafian said in a May 2024 statement. The pharma already has an imposing presence in ...